title: Bevacizumab in recurrent glioblastoma: five informative patient scenarios.
abstract: Glioblastoma is the most common and malignant primary brain tumour in adults. Maximum feasible surgical resection, radiotherapy and temozolomide chemotherapy at initial diagnosis have improved prognosis but rapid recurrence is typical and survival remains brief. There is an urgent need for effective new treatments and approval of the antiangiogenic agent bevacizumab for recurrent glioblastoma by Health Canada in 2009 has been the most notable recent therapeutic advance for this disease. This review with illustrative case studies highlights how bevacizumab has been incorporated into the treatment of glioblastoma in Canada and describes the ongoing controversies surrounding its clinical application.
authors: Department of Medicine,Princess Margaret Cancer Centre and University of Toronto,Toronto,Ontario,Canada.
authors: Warren P
authors: WP
authors: Mason
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D018450:Disease Progression; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012640:Seizures / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: vascular endothelial growth factor